|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 2101 L Street, NW |
Address2 | Suite 1000 |
| City | Washington |
State | DC |
Zip Code | 20037 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 16896-1006613
|
||||||||
|
6. House ID# 315950521
|
||||||||
| TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: K. LAURIE MCKAY |
Date | 10/20/2021 5:49:07 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Legislative and administrative monitoring and outreach on healthcare policy.
Legislative and administrative monitoring and outreach on prescription drug pricing/PBMs.
Legislative and administrative monitoring and outreach on policy issues affecting Medicaid programs.
Legislative and administrative monitoring and outreach on the implementation of the Affordable Care Act (ACA) (P.L. 111-148)
Legislative and administrative monitoring and outreach on issues regarding the health insurance tax (HIT).
Legislative outreach related to executive action surrounding the HHS Rebate rule.
S. 4775, Delivering Immediate Relief to America's Families, Schools and Small Businesses Act.
Legislative outreach and monitoring the implementation of H.R. 259, Medicaid Extenders Act of 2019 (P.L. 116-3).
Legislative outreach and monitoring the implementation of H.R. 1319, American Rescue Plan Act of 2021 (117-2).
Legislative and administrative monitoring and outreach on activity related to reconciliation and the congressional budget resolution.
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
H.R. 2297, MIND Act.
S. 439, Coronavirus Medicaid Response Act.
H.R. 1353, Coronavirus Medicaid Response Act.
S. 150, Ensuring Parity in MA for Audio-Only Telehealth Act of 2021.
H.R. 955, Medicaid Reentry Act of 2021.
H.R. 379, Improving Social Determinants of Health Act of 2021.
H.R. 2903, CONNECT for Health Act of 2021.
S. 1512 CONNECT for Health Act of 2021.
H.R. 3684, Infrastructure Investment and Jobs Act.
H.R. 4161 To amend title XIX of the Social Security Act to expand access to home and community-based services (HCBS) under Medicaid, and for other purposes.
S. 151, COVID HCBS Relief Act of 2021.
H.R. 525, COVID HCBS Relief Act of 2021.
H.R. 3203, To enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
S. 1388, Prescription Pricing for the People Act of 2021.
H.R. 928, American Family Act of 2021.
S. 773, A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
S. 1693, Medical Supplies for Pandemics Act of 2021.
H.R. 3463, Medical Supplies for Pandemics Act of 2021.
H.R. 5376, Build Back Better Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Rob |
Mangas |
|
|
|
Albert |
Wynn |
|
|
|
K. Laurie |
McKay |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |